title: Impact of coronary culprit lesion calcium in patients undergoing paclitaxel-eluting stent implantation (a TAXUS-IV sub study).
abstract: Randomized clinical trials have shown that paclitaxel-eluting stents significantly reduce restenosis after percutaneous coronary intervention. The impact of lesion calcification on the efficacy of paclitaxel-eluting stents is unknown. In the TAXUS-IV trial, 1,314 patients who underwent percutaneous coronary intervention were randomly assigned to a bare-metal or paclitaxel-eluting stent. By core laboratory analysis, 247 lesions (19%) were moderately or severely calcified. At the 9-month angiographic follow-up examination, the paclitaxel-eluting stent had significantly reduced the amount of late loss compared with the control stent (0.26 +/- 0.56 vs 0.51 +/- 0.48 mm, p = 0.015) within the analysis segment in the calcific lesions. The analysis segment restenosis rate was similar in patients with calcified and noncalcified lesions after paclitaxel-eluting stent implantation (7.5% vs 8.0%, respectively; p = 1.0). The rate of ischemia-driven target lesion revascularization (TLR) at 1 year was reduced by 56% in patients with calcified lesions (11.9% vs 5.1%, p = 0.09) and by 75% in noncalcified lesions (15.7% vs 4.3%, p <0.0001). By interaction testing, the efficacy of the paclitaxel-eluting stent in reducing TLR at 1 year was similar in the calcified and noncalcified lesions (p = 0.30). Moreover, by multivariate analysis, implantation of the paclitaxel-eluting stent was a powerful independent predictor of freedom from TLR, with similar hazard ratios for efficacy in calcified and noncalcified lesions (0.30 and 0.26, respectively). In conclusion, implantation of paclitaxel-eluting stents in patients with de novo coronary lesions significantly reduced restenosis in patients with and without calcified lesions.
authors.affiliation: Cardiovascular Research Foundation and Columbia University Medical Center, New York, NY, USA. im2132@columbia.edu
authors.forename: Issam
authors.initials: I
authors.lastname: Moussa
authors.forename: Stephen G
authors.initials: SG
authors.lastname: Ellis
authors.forename: Michael
authors.initials: M
authors.lastname: Jones
authors.forename: Dean J
authors.initials: DJ
authors.lastname: Kereiakes
authors.forename: Daniel
authors.initials: D
authors.lastname: McMartin
authors.forename: Barry
authors.initials: B
authors.lastname: Rutherford
authors.forename: Roxana
authors.initials: R
authors.lastname: Mehran
authors.forename: Michael
authors.initials: M
authors.lastname: Collins
authors.forename: Martin B
authors.initials: MB
authors.lastname: Leon
authors.forename: Jeffrey J
authors.initials: JJ
authors.lastname: Popma
authors.forename: Mary E
authors.initials: ME
authors.lastname: Russell
authors.forename: Gregg W
authors.initials: GW
authors.lastname: Stone
mesh_terms: D015906:Angioplasty, Balloon, Coronary / Q000295:instrumentation*; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D002114:Calcinosis / Q000150:complications / Q000000981:diagnostic imaging / Q000628:therapy*; D020099:Coated Materials, Biocompatible; D017023:Coronary Angiography; D023921:Coronary Stenosis / Q000000981:diagnostic imaging / Q000209:etiology / Q000628:therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008670:Metals; D008875:Middle Aged; D017239:Paclitaxel / Q000494:pharmacology*; D012720:Severity of Illness Index; D015607:Stents; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D020099:Coated Materials, Biocompatible; D008670:Metals; D017239:Paclitaxel